A review of retroperitoneal liposarcoma genomics.

Robert Tyler, Kasun Wanigasooriya, Philippe Taniere, Max Almond, Samuel Ford, Anant Desai, Andrew Beggs

Cancer treatment reviews 2020 Jun

filter terms:

Retroperitoneal liposarcomas are rare tumours that carry a poorer prognosis than their extremity counterparts. Within their subtypes - well differentiated (WDL), dedifferentiated (DDL), myxoid (MLS) and pleomorphic (PLS) - they exhibit a diverse genomic landscape. With recent advances in next generation sequencing, the number of studies exploring this have greatly increased. The recent literature has deepened our understanding of the hallmark MDM2/CDK4 amplification in WDL/DDL and addressed concerns about toxicity and resistance when targeting this. The FUS-DDIT3 fusion gene remains the primary focus of interest in MLS with additional potential targets described. Whole genome sequencing has driven identification of novel genes and pathways implicated in WDL/DDL outside of the classic 12q13-15 amplicon. Due to their rarity; anatomical location and histologic subtype are infrequently mentioned when reporting the results of these studies. Reports can include non-adipogenic or extremity tumours, making it difficult to draw specific retroperitoneal conclusions. This narrative review aims to provide a summary of retroperitoneal liposarcoma genomics and the implications for therapeutic targeting. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Citation

Robert Tyler, Kasun Wanigasooriya, Philippe Taniere, Max Almond, Samuel Ford, Anant Desai, Andrew Beggs. A review of retroperitoneal liposarcoma genomics. Cancer treatment reviews. 2020 Jun;86:102013